Cempra, Inc. (CEMP) Set to Announce Quarterly Earnings on Wednesday
Cempra, Inc. (NASDAQ:CEMP) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, October 25th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Cempra (NASDAQ:CEMP) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $3.58 million. During the same quarter in the prior year, the company earned ($0.51) EPS. The business’s revenue was down 74.9% compared to the same quarter last year. On average, analysts expect Cempra to post $-1 EPS for the current fiscal year and $-0.91 EPS for the next fiscal year.
Shares of Cempra, Inc. (CEMP) opened at 3.05 on Wednesday. The company’s 50-day moving average price is $3.13 and its 200-day moving average price is $3.70. Cempra, Inc. has a 12 month low of $2.55 and a 12 month high of $24.48. The company’s market cap is $160.15 million.
An institutional investor recently raised its position in Cempra stock. The Manufacturers Life Insurance Company lifted its position in Cempra, Inc. (NASDAQ:CEMP) by 5.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,499 shares of the biotechnology company’s stock after purchasing an additional 1,870 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of Cempra worth $182,000 at the end of the most recent quarter. Institutional investors own 49.75% of the company’s stock.
Several research analysts recently commented on CEMP shares. Jefferies Group LLC reissued a “hold” rating and set a $3.00 target price on shares of Cempra in a research note on Thursday, September 14th. Zacks Investment Research cut Cempra from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Roth Capital cut Cempra from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $4.00 in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $4.00 target price on shares of Cempra in a research note on Thursday, August 10th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cempra currently has an average rating of “Hold” and a consensus price target of $10.00.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.